Anticancer Drug Combinations, How Far We can Go Through?

Author(s): Da-Yong Lu, En-Hong Chen, Hong-Ying Wu, Ting-Ren Lu, Bin Xu, Jian Ding

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 17 , Issue 1 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Many clinical cancer therapies are less effective by using one anticancer drug only due to refractory properties of cancer pathogenesis and drug resistance property in advanced cancer patients. A general consensus among clinicians is that anticancer drug cocktail might better control cancer progresses and metastasis than single drug therapeutics in clinical trials. Despite great popularity, the anticancer drug combination dogma has not been established. The complexity of drug combination dogma discovery is more than we can expect now. This article speculates possible routes we can undertake in this matter. The background knowledge of drug combination therapy presently practiced and possible future landscapes and drawbacks of cancer drug combinative therapies are highlighted.

Keywords: Drug combination, drug resistance, neoplasm metastasis, biotherapy, cancer stem cell, personalized cancer therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 06 December, 2016
Page: [21 - 28]
Pages: 8
DOI: 10.2174/1871520616666160404112028
Price: $65

Article Metrics

PDF: 51
PRC: 1